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A B S T R A C T
Purpose: The aim of this study was to assess the atherogenicity risk of antiepileptics in children by
investigating the cascade, ‘‘hyperhomocysteinemia (HHcy) ! asymmetric dimethylarginine (ADMA)
increase ! nitric oxide (NO) decrease’’, which is thought to contribute to the developmental process of
atherosclerosis.
Methods: The participants included 53 epilepsy patients who received either valproic acid (VPA, n = 26)
or oxcarbazepine (OXC, n = 27). Twenty-four healthy sex- and age-matched children served as controls.
Fasting plasma total homocysteine (tHcy), ADMA and NO levels were measured.
Results: The differences in Hcy, ADMA, NO, vitamin B12 and folate levels between VPA, OXC and control
groups were all insigniﬁcant (p > 0.05 for all). In the patient group (VPA and OXC groups), 22.6% of the
children (12/53) had tHcy levels above the normal cutoff (13.1 mmol/l) for children and 17% of the
children (9/53) had tHcy levels of greater than 15 mmol/l which is accepted as the critical value for an
increased atherosclerosis risk (p < 0.05 for both). The difference in rate of HHcy between VPA and OXC
groups was statistically insigniﬁcant (p > 0.05, for both cut off levels of HHCy). There was a positive
correlation of tHcy levels and antiepileptic drug treatment duration in the patient group (r = +0.276,
p < 0.05).
Conclusion: HHcy may develop in patients using OXC. Contrary to some previous publications, our data
do not suggest that OXC is safer than VPA in terms of HHcy risk. Further prospective, large scale and
longer term studies investigating all suggested pathways responsible for development of atherosclerosis
due to HHcy should be conducted to deﬁne the exact mechanism responsible for AEDs related
atherosclerosis.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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During the last few years, it has been shown that risk factors for
atherosclerosis appear during childhood and adolescence and are
already at that time associated with atherosclerotic changes in
vessel walls.1 As is well known, endothelial dysfunction is
considered a precursor phenomenon. The concern is that
acceleration of this atherosclerotic process due to a variety of
unfavourable factors could lead to the emergence of cardiovascular* Corresponding author at: Gazi University, Faculty of Medicine, Department of
Pediatric Endocrinology, Besevler, TR-06450 Ankara, Turkey.
Tel.: +90 532 724 81 24; fax: +90 312 213 36 43.
E-mail address: hcemeksiz@gmail.com (H.C. Emeksiz).
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.11.007diseases earlier than would otherwise be expected. An increased
risk of fatal cardiovascular disease has been reported in patients
with epilepsy2. However, any relationship to antiepileptic drugs
(AEDs) remains unclear. Over the past two decades, high tHcy
levels, an independent risk factor for atherosclerosis, ADMA,
lipoprotein(a), and impaired lipid proﬁles, have been documented
in several studies with children on AEDs.3–9
The mechanisms underlying the cardiovascular pathophysiol-
ogy of HHcy are not yet fully understood. Numerous studies in
animals and humans have demonstrated that HHcy leads to
endothelial dysfunction due to decreased bioavailability of NO.
Nitric oxide is a powerful vasodilator and anti-atherogenic agent
that is produced in the endothelium from the amino acid L-
arginine via the action of endothelial nitric oxide synthase (eNOS).
One of the likely mechanisms of the decreased NO bioavailability invier Ltd. All rights reserved.
Table 1
Characteristics of VPA, OXC, and control groups.
Control group
(n = 24)
VPA group
(n = 26)
OXC group
(n = 27)
Gender M/F (n) 13/11 16/10 11/16
Mean age (SD, years) 12.1  3.3 10.9  3.1 10.8  3.2
Mean duration of treatment
(SD, years)
3.4  1.7 2.7  1.4
Mean dose (SD, mg/kg/d) 22.7  7.0 22.5  6.7
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inhibitor of eNOS, which, in turn, is followed by reduced synthesis
of NO.10
Asymmetric dimethylarginine is also considered to be a
potential risk factor for the development of atherosclerosis.11 It
has been suggested that elevated levels of ADMA are associated
with the severity of cardiovascular events.12,13 Asymmetric
dimethylarginine is produced from methylated proteins derived
from homocysteine (Hcy) metabolism. It competes with L-arginine
and causes a reduction in NO formation in the vascular wall.
Plasma tHcy has been shown to increase endothelial cell
generation of ADMA by inhibiting the activity of the enzyme
dimethylarginine dimethylaminohydrolase (DDAH), which is
responsible for ADMA metabolism.14,15
Valproic acid (VPA) and oxcarbazepine (OXC) are widely used
AEDs in childhood epilepsy. In this study, we assessed whether
children on these common antiepileptics had an increased risk of
atherosclerotic diseases by investigating NO levels for the ﬁrst
time, in addition to tHcy and ADMA levels, and assessing possible
associations among them.
2. Patients and methods
The study group consisted of 53 patients with epilepsy (26 girls,
27 boys) treated in the Department of Paediatric Neurology at Gazi
University Faculty of Medicine (Table 1). All patients had received
antiepileptic monotherapy (VPA, n = 26; OXC, n = 27) for at least 1
year. The presence of epilepsy due to cerebrovascular disease as
well as mass lesions, history of cardiac or peripheral vascular
disease, and renal, hepatic, or thyroid disease were exclusion
criteria. Subjects using any other medication or vitamins were also
excluded. All patients were judged to be in good health and free of a
history of bleeding or thrombosis. A total of 24 healthy children
served as the control group. This study was approved by the local
ethics committee. Informed consent was obtained from parents.
Fasting venous blood samples were obtained from patients and
controls to measure tHcy, NO, and ADMA levels. Serum and plasma
were separated as soon as possible by centrifugation (5 min,
3000  g). The samples were stored at 80 8C until assayed.
Plasma tHcy concentrations and ADMA levels were measured by
high-performance liquid chromatography, and serum nitric oxide
levels by an incubation assay method. Plasma tHcy levels
13.1 mmol/l were deemed to indicate hyperhomocysteinemia.16Table 3
Comparison of the patients and control group for HHcy according to cutoff values.
Control group (n = 24) 
tHcy > 13.1 (mmol/l), n (%) – 
tHcy > 15.0 (mmol/l), n (%) – 
a p-Value, compared between control and patient groups.
Table 2
Comparison of tHcy, ADMA, and NO levels.
Control groupa (n = 24) VPA 
tHcy (mmol/l) 9.2 (6.6–11.3) 9.2
ADMA (mmol/l) 2.1 (2.0–2.3) 2.1
NO (mmol/l) 1.8 (1.4–2.3) 1.8
Folic acid (ng/ml) 8.87 (7.27–10.66) 7.7
Vitamin B12 (pg/ml) 499.1 (385.6–678.3) 439.8
a Values are expressed as median and median (25–75th percentiles).
b p-Value, compared with control, VPA, and OXC groups.2.1. Statistical analyses
All statistical calculations were performed using the SPSS 11.5
software. Descriptive statistics were computed as means  stan-
standard deviations and median (25–75th percentiles). Differences
between groups were assessed using one-way analysis of variance,
Pearson’s chi-squared test, the Mann–Whitney U-test, and the
Kruskal–Wallis test. The linear relationships between variables were
evaluated using Spearman’s rho coefﬁcient. Statistical signiﬁcance
was set at p < 0.05.
3. Results
In total, 53 idiopathic epilepsy patients and 24 controls
participated. Gender and mean age distributions did not differ
signiﬁcantly between the groups (p > 0.05 for both; Table 1). None
of the differences in tHcy, ADMA, NO, vitamin B12, and folate levels
among the VPA, OXC, and control groups was signiﬁcant (all
p > 0.05; Table 2). No signiﬁcant relationship was found among
tHcy, NO, and ADMA levels (p > 0.05 for all). In the patient group,
22.6% (12/53) of the children had tHcy levels above the normal
cutoff level (13.1 mmol/l), and 17% (9/53) of the children had tHcy
levels greater than 15 mmol/l, the critical value for increased
atherosclerosis risk. In contrast, no subject in the control group had
tHcy levels above these values (Table 3). The difference in HHcy
between the VPA and OXC groups was not statistically signiﬁcant
(p > 0.05 for both cutoff levels of HHcy). In the patient group, a
statistically signiﬁcant correlation was detected between the
duration of treatment and tHcy level (r = +0.276, p < 0.05),
whereas no such correlation was detected for the NO and ADMA
levels (p > 0.05 for both). No statistically signiﬁcant difference was
found in ADMA and NO levels between patients with tHcy abovePatient group (n = 53) p
VPA group (n = 26) OXC group (n = 27)
6 (23.1) 6 (22.2) 0.014a
5 (19.2) 4 (14.8) 0.049a
groupa (n = 26) OXC groupa (n = 27) p
 (6.5–12.8) 9.3 (8.2–13.5) >0.05b
 (2.0–2.3) 2.2 (1.8–2.3) >0.05b
 (1.3–2.7) 2.3 (1.4–3.1) >0.05b
8 (6.08–9.40) 8.43 (6.45–10.67) >0.05b
 (319.7–544.3) 489.9 (378.5–640.9) >0.05b
H.C. Emeksiz et al. / Seizure 22 (2013) 124–12712613.1 mmol/l or 15.1 mmol/l and patients with tHcy levels below
these cutoff values (p > 0.05, for both).
4. Discussion
To our knowledge, this is the ﬁrst reported study to evaluate
atherosclerosis risk in children receiving AEDs associated with the
HHcy ! ADMA ! NO cascade. Hyperhomocysteinemia was deter-
mined in approximately one-quarter of the patients taking AEDs,
and the level of HHcy was the same in the VPA and OXC groups.
Additionally, there was a positive correlation between tHcy levels
and antiepileptic drug treatment duration in the patient group.
There was no signiﬁcant difference in tHcy, serum ADMA, and NO
levels among the VPA, OXC, and control groups.
Hyperhomocysteinemia is an independent risk factor for
cardiovascular and cerebrovascular diseases and thrombosis.18
Many reported studies have proposed that AEDs may result in HHcy,
but its frequency varies over a wide range in different population-
based studies. In paediatric studies, HHcy has been observed in as
many as 40% of the children receiving AEDs.18,19 It is difﬁcult to build
a consensus for a cutoff level for HHcy due to variations in ethnicity,
food consumption, and life styles among populations.20 There are
also limited data on tHcy levels in healthy Turkish children. To our
knowledge, the report by Dinleyici et al.16 is the only one that
provides a paediatric cutoff (13.1 mmol/l) in Turkish children for
HHcy. In our study, 12 of 53 patients (22.6%) had HHcy (>13.1 mmol/
l), and nine of 53 patients (17%) had tHcy levels greater than
15 mmol/l, accepted as the critical value for increased atherosclero-
sis risk.17 Although it is known to induce HHcy, VPA is still widely
prescribed in neurology clinics. The mechanism by which VPA
induces HHcy is not fully understood.19,20 Moreover, data about the
probable effects of new-generation AEDs, such as OXC, lamotrigine
(LTG), levatiracetam (LEV), and topiramate (TPM), on Hcy metabo-
lism are still limited.21,22 These drugs may be safer than old-
generation AEDs in children with epilepsy who are at increased risk
for early atherosclerosis development, such as those with familial
hyperlipidaemia or genetic disorders of Hcy metabolism. However,
as yet, there are too few studies in the literature comparing new- and
old-generation AEDs on this issue.19 Oxcarbazepine possesses
chemical features similar to those of its parent compound
carbamazepine (CBZ). Compared with CBZ, OXC has a reduced
capacity for inducing hepatic cytochrome P450 enzymes and thus of
interacting with other drugs.23 As a result, OXC has replaced CBZ for
certain indications.21 One purpose of the present study was to
evaluate whether OXC affected tHcy levels and to compare OXC with
VPA in terms of HHcy. In our study, HHcy was detected in six patients
(22.2%), which was not different from HHcy in the VPA group. Kurul
et al.22 reported that no child using OXC developed HHcy in their
study. However, a major limitation of their study was the small
sample size. A study of adults conducted by Belcastro et al.21 did
reveal that new-generation AEDs such as OXC and TPM may induce
HHcy. They also proposed that LTG and LEV, also classiﬁed as new-
generation AEDs, had no effect on Hcy metabolism. Considering
these results, HHcy may develop due to OXC treatment. Thus,
clinicians should be careful about prescribing OXC in patients with
additional risks for atherosclerosis and instead, safer new-genera-
tion AEDs, such as LTG and LEV, which are believed to have no
deleterious effect on Hcy metabolism, should be used.
Deﬁciencies in vitamins acting as cofactors and genetic
polymorphisms in genes encoding enzymes involved in Hcy
metabolic pathways may result in HHcy.19 Two important cofactors,
vitamin B12 and folate, are tightly connected with Hcy metabo-
lism.19,20,24 Reduced plasma levels of these cofactors have been
reported in children under VPA or CBZ treatment.25,26 However, the
exact mechanism(s) by which different AEDs exert their effects on
vitamin metabolism and thus result in HHcy are incompletelyunderstood.19 The proposed mechanisms responsible for vitamin
depletion in patients under AED treatment can be summarised as
interference with vitamin absorption from the intestinal mucosa,
increased requirements of vitamins due to dysfunction in Hcy
metabolism, and the induction of liver enzymes responsible for
increased vitamin metabolism.20,27 There are also contrary reports
in the literature revealing unchanged or increased levels of these
vitamins in patients taking AEDs.28–31 In our study, no vitamin B12 or
folate deﬁciency was detected in patients receiving AEDs. Moreover,
there was also no signiﬁcant difference in vitamin B12 and folate
levels between patients with HHcy and without HHcy. Some studies
conducted in patients receiving AEDs found increased Hcy levels in
patients carrying methylenetetrahydrofolate reductase (MTHFR)
and cystathionine beta-synthase (CBS) gene polymorphisms.19,20
Additionally, an experimental study conducted on pregnant Wistar
rats demonstrated that VPA caused HHcy by directly impairing
methionine synthase (MS) activity.32A major limitation of our study
was that we did not perform a genetic work-up of our patients for the
MTFR and CBS genes, which are known to play a role in Hcy
metabolism. Further studies concerning the probable mechanisms
by which OXC causes HHcy and/or examining whether OXC is
related to genetic polymorphisms involved in Hcy pathways may
help in better understanding the actions of OXC in Hcy metabolism.
Some reports have noted a progressive increase in tHcy levels as
the use of AEDs was prolonged and/or involved multiple-AED
treatment.18,25,29 Ono et al.27 reported an increased risk of HHcy in
patients receiving multiple and prolonged (>7 years) AED
medication. Similarly, Vilaseca et al.29 reported an increase in
tHcy level in parallel with the duration of AED use in children with
seizure disorder. We also detected a weak but signiﬁcant
correlation between tHcy level and duration of AED use. All
patients in our study received AED monotherapy. Children with
epilepsy may require long-term, even life-long AED treatment.
Because HHcy itself can cause an epileptic seizure, patients
with epilepsy may require multiple AEDs to prevent seizures.19
Prospective studies may be designed to determine the time
required until the cutoff value for HHcy is reached by certain AEDs
that are already known to induce HHcy. Thus, long-term morbidity
due to these drugs may be preventable by switching the drugs
before reaching the critical cutoff value for HHcy.
Hyperhomocysteinemia gives rise to enhanced ADMA produc-
tion. A higher plasma level of ADMA exerts its atherogenic effect by
lowering NO levels. This is one of the major suggested mechanisms
by which ADMA and Hcy may lead to atherosclerosis.33,34 To our
knowledge, only a few reported studies have investigated ADMA as
a marker of endothelial dysfunction and its relation with Hcy in
patients receiving AEDs.4,5 Oz et al.4 ﬁrst reported signiﬁcantly
elevated ADMA levels in adult patients taking VPA. Similar results
have also been reported in children. Ozdemir et al.5 noted
increased serum ADMA levels and increased tHcy levels in
epileptic children receiving VPA monotherapy. However, in neither
study a signiﬁcant relationship between Hcy and ADMA was
reported. Moreover, no signiﬁcant ADMA elevation accompanying
HHcy was detected in patients with vascular disease and under
long-term multiple AED treatment.35,36 Similarly, we found no
signiﬁcant difference in ADMA levels between the study and
control groups or between patients with and without HHcy. We
also found no signiﬁcant relationship between Hcy and ADMA
levels. These results may be explained in two different ways. It has
been proposed that more than one mechanism plays a role in the
development of atherosclerosis and vascular disease due to HHcy.
The Hcy–ADMA–NO cascade evaluated in our study is one of these.
Other mechanisms suspected in atherosclerosis development due
to HHcy are summarised as oxidative modiﬁcations of low density
lipoproteins, direct oxidative damage to endothelial cells, promo-
tion of thrombosis due to loss of endothelial cell anti-thrombotic
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process of atherogenesis.19,37 Another reason for the results noted
above may be related to factors affecting ADMA metabolism, as
noted in previous reports.35,36
NO is the major molecule that contributes to the anti-
atherosclerotic effects of the endothelium through its biological
properties, such as vasodilatation, inhibition of platelet aggrega-
tion, leucocyte adhesion to the vascular endothelium, and
protection of plasma LDL against oxidation.10 Thus, a decrease
in NO levels contributes to the destructive process. However, to
date, no reported study has investigated NO levels together with
Hcy and ADMA levels in children taking AEDs. We found no
signiﬁcant difference in NO levels between control and patient
groups. Moreover, no signiﬁcant correlation with Hcy–ADMA–NO
levels was found. In our study, the absence of a signiﬁcant increase
in ADMA levels between groups may be one reason for our not
ﬁnding a signiﬁcant change in NO levels. Our study design was
cross sectional. Thus, we did not know baseline Hcy, ADMA, and
NO values of the patients before the start of AED treatment. By
taking these factors into consideration, further studies with a
relatively larger sample size may clarify whether the suggested
association occurs among Hcy, ADMA, and NO in children taking
AEDs.
5. Conclusion
A signiﬁcant level of hyperhomocysteinemia may develop in
patients using OXC, which is a new-generation AED. Thus, contrary
to some reports, OXC may not be a safe choice for patients who
already possess additional risk factors for the development of
HHcy. Although we found no signiﬁcant differences in Hcy, NO, and
ADMA levels between study and control groups, further prospec-
tive large-scale and longer term studies investigating all pathways
suggested to be responsible for the development of atherosclerosis
due to HHcy should be conducted to deﬁne the exact mechanism(s)
responsible for AEDs related atherosclerosis.
Conﬂicts of interest: The authors declare that there is no conﬂict
of interest in this paper.
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